Literature DB >> 3888102

Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.

B E Gilbert, S Z Wilson, V Knight, R B Couch, J M Quarles, L Dure, N Hayes, G Willis.   

Abstract

In a double-blind study of influenza in a population of college students in 1984, ribavirin small-particle aerosol treatment of 38 patients (18 treated, 20 control) infected with a new antigenic variant, influenza virus strain A/Victoria/7/83 (H1N1), was associated with statistically significant reductions in the height and duration of fever, systemic symptoms, and virus shedding. Patients received a total of 2.4 g of ribavirin over 42 h during 68 h of hospitalization without any side effects. In addition, in a study of patients infected with influenza virus strain B/Texas/1/84 (seven treated, eight control) treated with ribavirin aerosol showed a trend of more rapid recovery than control patients.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3888102      PMCID： PMC176267          DOI： 10.1128/AAC.27.3.309

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Treatment of influenza A (H1N1) virus infection with ribavirin aerosol.

Authors:  S Z Wilson; B E Gilbert; J M Quarles; V Knight; H W McClung; R V Moore; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

2.  Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses.

Authors:  A L Frank; R B Couch; C A Griffis; B D Baxter
Journal:  J Clin Microbiol       Date:  1979-07       Impact factor: 5.948

3.  Ribavirin small-particle aerosol treatment of influenza.

Authors:  V Knight; H W McClung; S Z Wilson; B K Waters; J M Quarles; R W Cameron; S E Greggs; J M Zerwas; R B Couch
Journal:  Lancet       Date:  1981-10-31       Impact factor: 79.321

4.  Maintenance of viability and comparison of identification methods for influenza and other respiratory viruses of humans.

Authors:  B D Baxter; R B Couch; S B Greenberg; J A Kasel
Journal:  J Clin Microbiol       Date:  1977-07       Impact factor: 5.948

5.  Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.

Authors:  C B Hall; J T McBride; E E Walsh; D M Bell; C L Gala; S Hildreth; L G Ten Eyck; W J Hall
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

6.  Ribavirin aerosol treatment of influenza B virus infection.

Authors:  H W McClung; V Knight; B E Gilbert; S Z Wilson; J M Quarles; G W Divine
Journal:  JAMA       Date:  1983-05-20       Impact factor: 56.272

7.  Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement.

Authors:  A L Frank; J Puck; B J Hughes; T R Cate
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948
  7 in total
  22 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 2.  Screening for new agents.

Authors:  B Oberg; L Vrang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 4.  Pandemic and seasonal influenza: therapeutic challenges.

Authors:  Matthew J Memoli; David M Morens; Jeffery K Taubenberger
Journal:  Drug Discov Today       Date:  2008-05-15       Impact factor: 7.851

Review 5.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

6.  High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay.

Authors:  G G Granich; D J Krogstad; J D Connor; K L Desrochers; C Sherwood
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

Review 7.  Antiviral therapy with small particle aerosols.

Authors:  V Knight; B Gilbert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

8.  MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.

Authors:  Brian E Gilbert; Matthew T McLeay
Journal:  Antiviral Res       Date:  2008-02-04       Impact factor: 5.970

9.  Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Scott A Harper; John S Bradley; Janet A Englund; Thomas M File; Stefan Gravenstein; Frederick G Hayden; Allison J McGeer; Kathleen M Neuzil; Andrew T Pavia; Michael L Tapper; Timothy M Uyeki; Richard K Zimmerman
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

10.  Hemodialysis clearance of intravenously administered ribavirin.

Authors:  T H Kramer; G G Gaar; C G Ray; L Minnich; J G Copeland; J D Connor
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.